Search results
Ampligen continues to be evaluated, and as of May 2021 is the subject of phase 2 and phase 3 trials to potentially treat myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and several cancers. As of 2021, there is limited scientific evidence supporting the therapeutic efficacy of rintatolimod in treating CFS.
17 maj 2022 · In AMPLIGEN: THE BATTLE FOR A PROMISING ME/CFS DRUG—with an Introduction and Overview From 2022—Ostrom covers the development of Ampligen from the 1960s through the present day and provides investigations that appeared in the NEW YORK NATIVE from 1993 to 1997.
21 lis 2023 · The AMP-518 clinical trial is a two-arm, randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of Ampligen in subjects experiencing the post-COVID condition of fatigue. The primary protocol planned outcome measure of the study is change from baseline to week 13 in PROMIS® Fatigue Score.
10 lip 2023 · The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
24 lip 2024 · The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
22 lis 2023 · AIM ImmunoTech has concluded subject dosing in the Phase II clinical trial of its investigational drug, Ampligen, to treat individuals with post-Covid fatigue. The randomised, two-arm, placebo-controlled, double-blind, multicentre AMP-518 trial is designed to assess the safety and efficacy of Ampligen.
30 kwi 2024 · US-based biotechnology company AIM ImmunoTech has reported significant progress in its Phase Ib/II DURIPANC trial, which is assessing the combination of Ampligen and Imfinzi for treating late-stage pancreatic cancer patients.
